VolitionRx Limited (VNRX) Stock Price

VNRXStock

$0.18−97.99%52W

Market Cap$5.41M

P/E—

PEG Ratio—

Div yield—

Beta1.19

VNRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-104.28%

Price vs S&P 500 (4W)-30.69%

VGM Score48.13

Book Value / Share (Quarterly)$0.07

P/TBV (Annual)9.49x

Revenue Growth (3Y)77.29%

Cash Flow / Share (Quarterly)$-1.63

Price vs S&P 500 (YTD)-108.40%

Net Profit Margin (TTM)-1043.10%

EPS (TTM)$-3.80

10-Day Avg Trading Volume1.02M

EPS Excl Extra (TTM)$-3.80

Revenue Growth (5Y)180.21%

EPS (Annual)$-4.37

ROI (Annual)-122.64%

Net Profit Margin (5Y Avg)-9529.48%

Cash / Share (Quarterly)$0.23

Revenue Growth QoQ (YoY)-1.97%

ROA (Last FY)-338.45%

Revenue Growth TTM (YoY)86.32%

EBITD / Share (TTM)$-2.90

ROE (5Y Avg)-136.80%

Operating Margin (TTM)-855.60%

Cash Flow / Share (Annual)$-3.14

P/B Ratio0.86x

P/B Ratio (Quarterly)18.58x

Net Income / Employee (Annual)$-311,400

EV / Revenue (TTM)5.63x

Net Interest Coverage (TTM)-8.44x

ROA (TTM)-334.21%

EPS Incl Extra (Annual)$-4.37

Current Ratio (Annual)0.17x

Quick Ratio (Quarterly)0.25x

3-Month Avg Trading Volume6.16M

52-Week Price Return-97.99%

Revenue / Employee (TTM)$32,800

Tangible BV / Share (Quarterly)$0.07

P/S Ratio (Annual)2.91x

Asset Turnover (Annual)0.25x

52-Week High$10.31

Operating Margin (5Y Avg)-9964.11%

EPS Excl Extra (Annual)$-4.37

CapEx CAGR (5Y)-45.94%

Tangible BV CAGR (5Y)-2.94%

26-Week Price Return-94.37%

Quick Ratio (Annual)0.13x

13-Week Price Return-83.63%

Total Debt / Equity (Annual)0.22x

Current Ratio (Quarterly)0.30x

Enterprise Value$13.85M

Revenue / Share Growth (5Y)338.27%

Asset Turnover (TTM)0.32x

Book Value / Share Growth (5Y)-16.26%

Revenue / Employee (Annual)$23,000

Pretax Margin (Annual)-1360.63%

Cash / Share (Annual)$0.18

3-Month Return Std Dev128.44%

Net Income / Employee (TTM)$-341,900

ROE (Last FY)-149.44%

Net Interest Coverage (Annual)-6.02x

EPS Basic Excl Extra (Annual)$-4.37

Receivables Turnover (TTM)10.53x

Total Debt / Equity (Quarterly)0.79x

EPS Incl Extra (TTM)$-3.80

Receivables Turnover (Annual)8.06x

ROI (TTM)-191.86%

P/S Ratio (TTM)2.04x

Pretax Margin (5Y Avg)-9606.40%

Revenue / Share (Annual)$0.32

Tangible BV / Share (Annual)$0.33

Price vs S&P 500 (52W)-113.52%

Year-to-Date Return-96.48%

5-Day Price Return-11.32%

EPS Normalized (Annual)$-4.37

ROA (5Y Avg)-202.93%

Net Profit Margin (Annual)-1352.17%

Month-to-Date Return-30.19%

Cash Flow / Share (TTM)$-0.50

EBITD / Share (Annual)$-3.84

Operating Margin (Annual)-1258.47%

LT Debt / Equity (Annual)0.14x

ROI (5Y Avg)-107.56%

LT Debt / Equity (Quarterly)0.49x

EPS Basic Excl Extra (TTM)$-3.80

P/TBV (Quarterly)18.81x

P/B Ratio (Annual)9.37x

Pretax Margin (TTM)-1046.82%

Book Value / Share (Annual)$0.33

Price vs S&P 500 (13W)-86.31%

Beta1.19x

P/FCF (Annual)125.63x

Revenue / Share (TTM)$0.27

ROE (TTM)-376.59%

52-Week Low$0.17

vGradeB

gGradeB

mGradeF

vgmGradeC

VNRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.67	-$0.59	+12.66%(+$0.08)
Q1 2026	May 14, 2026	-$0.73	-$0.84	-14.23%(-$0.10)
Q4 2025	Mar 31, 2026	-$0.80	-$0.91	-13.50%(-$0.11)
Q3 2025	Nov 13, 2025	-$1.04	-$1.06	-1.56%(-$0.02)
Q2 2025	Aug 14, 2025	-$1.00	-$1.31	-30.60%(-$0.31)

VNRX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About VolitionRx Limited

VolitionRX Ltd develops blood-based diagnostic tests using its proprietary Nucleosomics platform to identify disease markers from circulating nucleosomes. The company's tests provide simple, cost-effective alternatives for diagnosing and monitoring cancers, sepsis, COVID-19, and other serious diseases. VolitionRX operates in both human and veterinary diagnostics, targeting underserved markets with accessible diagnostic solutions.